Ribon Therapeutics, a Cambridge, Mass.-based clinical stage biotechnology company developing therapeutics targeting stress support pathways in cancer and inflammation, closed a $65m financing.
The round was led by Deerfield Management and U.S. Venture Partners, with support from new investors Avego BioScience Capital, GV (formerly Google Ventures), Monashee Investment Management and Peregrine Ventures, along with existing investors AbbVie Ventures, Bristol Myers Squibb, Euclidean Capital, Johnson & Johnson Innovation – JJDC, Inc., Novartis Venture Fund, Osage University Partners, Takeda Ventures and The Column Group.
The company will use the proceeds to support the clinical development of its novel precision medicine candidates.
Led by Victoria Richon, Ph.D., President and Chief Executive Officer, Ribon Therapeutics is a clinical stage biotechnology company developing therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. The company is exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. Leveraging its proprietary BEACON+ (Blocking the Enzyme Activity Component of NAD+) platform, the company is building a pipeline of selective, small molecule inhibitors to numerous NAD+-utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas. The lead program is RBN-2397, a PARP7 inhibitor in clinical development for the treatment of cancer.
FinSMEs
14/07/2021